First-in-Class Drug Wins FDA Approval for Polycythemia Vera
(MedPage Today) — The FDA approved first-in-class rusfertide (Mimrylo) for treating erythrocytosis in adults with polycythemia vera (PV), a rare and slow-growing hematologic malignancy. Rusfertide mimics hepcidin, the natural hormone involved… Source link
